At a glance
ClinicalIndex Comparison RecordN/ACompleted· 4,068 enrolled
Drug / intervention
5ARI + ABdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Evaluating the Impact of Early Versus Delayed 5 Alpha Reductase Inhibitor Treatment on the Risk of Emergent Surgery in Men With Benign Prostatic Hyperplasia
In Brief
An observational study evaluating 5ARI + AB for Prostatic Hyperplasia. Completed, enrolled 4,068 participants.
Detailed Summary
This retrospective study aims to assess the impact of early vs delayed 5-alpha-reductase inhibitor (5ARI) therapy in patients with BPH on alpha-blocker (AB) therapy and the risk of acute urinary retention (AUR), prostate-related surgery, and emergency surgery (defined as prostate surgery occurring within 30 days of AUR). The MarketScan database will be utilized for this study (2000-2008).
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsProstatic Hyperplasia
Countries--
Collaborators--
Timeline
N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartAug 2010
Primary CompletionAug 2010
First PostedApr 2011
TodayJul 2026
First PostedApr 11, 2011
Enrollment StartAug 1, 2010
Primary CompletionAug 1, 2010
TodayJul 2, 2026
Enrollment to primary: 0 daysPosted 15.2 years ago
Interventions
5ARI + ABdrug
5ARI: Dutasteride or Finasteride and any AB: Doxazosin, Prazosin, Tamsulosin, Terazosin or Alfuzosin